Flu and RSV Surge Linked to Rising Pertussis Cases

The Pan American Health Organization (PAHO) has raised an alarming epidemiological alert regarding a spike in pertussis cases across several countries in the Americas. This warning comes on the heels of declining vaccination coverage during the COVID-19 pandemic, which had previously led to a significant drop in global pertussis cases.

Historically low case numbers in 2021 have given way to a troubling trend, with reported cases rising sharply in 2023 to approximately 4,100 in the Americas. The situation worsened in 2024, with nearly 44,000 cases logged.

U.S. Leads with a Record Number of Cases

The United States is at the forefront of this health crisis, reporting a staggering 10,062 pertussis cases as of late April. Tragically, five deaths, including four infants under one year old, have been attributed to this outbreak. States like Washington, Oregon, and California are experiencing the highest case totals, particularly among adolescents aged 11 to 19.

Countries such as Brazil, Mexico, Ecuador, Peru, Colombia, and Paraguay are also witnessing a rise in cases. PAHO has urged these nations to enhance surveillance and vaccination efforts, especially for young children who are most vulnerable.

Salmonella Outbreak Linked to Cucumbers Raises Alarm

In a separate health alert, the U.S. Centers for Disease Control and Prevention (CDC) reported that a multistate Salmonella outbreak associated with whole cucumbers has surged from 26 to 45 cases in just two weeks. The outbreak now spans 18 states, with illnesses traced back to cucumbers distributed by Fresh Start Produce, Inc.

Though no deaths have been recorded, 16 individuals have required hospitalization. Florida and Georgia lead with seven cases each, raising concerns that many infected may have traveled on the same cruise ships from Florida.

New Vaccines to Combat COVID-19 and Flu Risks

In promising news for COVID-19 prevention, Moderna announced that its next-generation vaccine, mNexspike (mRNA-1283), has received FDA approval. This updated formula targets the SARS-CoV-2 spike protein more efficiently, requiring only a fifth of the dosage compared to its predecessor, Spikevax (mRNA-1273). This vaccine is expected to be available in time for the upcoming respiratory virus season.

Importantly, mNexspike is currently recommended only for high-risk groups, namely adults aged 65 and older and those aged 12 to 64 with higher risk conditions.

Concerning Findings on Raw Milk and H5N1 Flu